COYA (Coya Therapeutics) EPS (Basic): $-1.07 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COYA Coya Therapeutics Inc COYA
49 GF Score
Price $4.39
GF Value $6.54
Valuation Significantly Undervalued
View Full Analysis

What is Coya Therapeutics EPS (Basic)?

Coya Therapeutics COYA -3.10% 49 EPS (Basic) is $-1.07 as of Jun. 2026. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued).

Coya Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2026 was $-0.28. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.07.

Coya Therapeutics's EPS (Diluted) for the three months ended in Jun. 2026 was $-0.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.07.

Coya Therapeutics's EPS without NRI for the three months ended in Jun. 2026 was $-0.28. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was -1.07.

During the past 3 years, the average EPS without NRI Growth Rate was 30.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Coya Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 30.40% per year. The lowest was -9.80% per year. And the median was 10.30% per year.

Coya Therapeutics  (NAS:COYA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Coya Therapeutics EPS (Basic) Related Terms

Coya Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Coya Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coya Therapeutics EPS (Basic) Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -0.74 -4.73 -0.79 -0.98 -1.27

Coya Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.13 -0.34 -0.32 -0.28
COYA
49GF Score
Coya Therapeutics Inc COYA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coya Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Coya Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-21.226-0)/16.730
=-1.27

Coya Therapeutics's Basic EPS for the quarter that ended in Jun. 2026 is calculated as

Basic EPS (Q: Jun. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.638-0)/23.457
=-0.28

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.07 mean?
Coya Therapeutics (COYA) has a EPS (Basic) of $-1.07 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coya Therapeutics and its competitors.
Is Coya Therapeutics' EPS (Basic) too high?
Coya Therapeutics' current EPS (Basic) is $-1.07. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' EPS (Basic) compare to ONCY and GUTS?
Coya Therapeutics' EPS (Basic) of $-1.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coya Therapeutics and its competitors. Coya Therapeutics's current EPS (Basic) is $-1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current EPS (Basic) is $-1.07. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current EPS (Basic) is $-1.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coya Therapeutics (COYA) Overvalued in 2026?

Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued. The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54. GuruFocus considers Coya Therapeutics to be Significantly Undervalued.

Key valuation signals for COYA:

  • EPS (Basic): $-1.07
  • GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
  • GF Score™: 49/100

No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coya Therapeutics Business Description

Address 5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score

Get the complete analysis for COYA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.39
Price
$6.54
GF Value